AssetMark Inc’s Telix Pharmaceuticals TLX Stock Holding History

AssetMark Inc’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13K	Buy	185 +32	+21%	+$326	﹤0.01%	2945
2026 Q1	$1.46K	Buy	153 +108	+240%	+$823	﹤0.01%	2949
2025 Q4	$337	Buy	45 +4	+10%	+$38	﹤0.01%	3172
2025 Q3	$392	Buy	41 +23	+128%	+$282	﹤0.01%	2970
2025 Q2	$289	Buy	+18	New	+$302	﹤0.01%	2825

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

AssetMark Inc's TLX Position: Q2 2026 in Review

AssetMark Inc increased its Telix Pharmaceuticals (TLX) stake by 21% in Q2 2026, buying an estimated $326 and bringing the position to 185 shares worth $2.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2945.

AssetMark Inc first reported a position in TLX in Q2 2025 and has held it in 5 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

AssetMark Inc held 185 shares of Telix Pharmaceuticals worth $2.13K as of Q2 2026.
AssetMark Inc bought 32 Telix Pharmaceuticals shares in Q2 2026, an estimated $326.
Telix Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2945 holding.
AssetMark Inc first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.